Madrigal Pharmaceuticals, Inc.
MDGL
Jodie situation report
Madrigal Pharmaceuticals, Inc.'s move is being confirmed by its market group.
No new filing conclusion is available. 8 of 13 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 4 directly disclosed connections are confirming.
- At least 9 of 13 members remain active in the next snapshot.
- Capital-flow agreement rises above 55%.
- A filing-linked outsider such as BMRN begins moving with the group.
Invalidation: The live read weakens if participation falls to 4 of 13 members or fewer.
Who this business touches
The relationships behind MDGL
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Depends on
PFEPfizer, Inc.partnerMay 6, 2026 ▾
“Key Developments In January 2026, we announced the expansion of our pipeline with an exclusive global license with Pfizer Inc.”
HTGCHercules Capital, Inc.lenderMay 6, 2026 ▾
“Credit Facilities Hercules Loan Facility In May 2022 we entered into a $250.0 million senior secured loan facility with Hercules Capital, Inc.”
Depended on by
ARWRArrowhead Pharmaceuticals, Inc.partnerMay 7, 2026 ▾
“Announced an exclusive worldwide license agreement with Madrigal Pharmaceuticals for ARO-PNPLA3, Arrowhead’s clinical stage RNA interference (RNAi) therapeutic designed to reduce liver expression of patatin-like phospholipase domain containing 3 (PNPLA3) as a…”
Filing peers
Companies whose filings use similar operating language.
Open the three relationships above to see Jodie’s filing proof. Pro unlocks 2 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →
What is moving around it
Live connections
MDGL is currently a Participant in the organic co-movement group Biotechnology Therapeutics. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.